Loomis Sayles & Co L P Reduces $6M in Alkermes plc ($ALKS)

Loomis Sayles & Co L P has trimmed its position in Alkermes plc (NasdaqGS: ALKS) by 6.2%, according to its latest Form 13F filing with the SEC. The firm sold 117,941 shares, leaving it with 1,784,581 shares valued at approximately $85.96 million as of the reporting period.

What Changed in Loomis Sayles's Alkermes Position

Loomis Sayles reduced its holdings in Alkermes by 6.2%, bringing its share count down from 1,902,522 to 1,784,581. This adjustment reflects a decrease of 117,941 shares, with the total value of the position now at about $85.96 million.

Other Institutional Activity in Alkermes

BlackRock, Inc. increased its stake in Alkermes by 41,998 shares, ending with 28,314,410 shares worth around $1.00 billion. Baker Bros. Advisors LP maintained its position with 10,012,267 shares valued at $354.03 million. Vanguard Portfolio Management LLC opened a new position with 9,511,112 shares, valued at approximately $336.31 million. State Street Corp slightly reduced its holdings by 7,572 shares, now holding 9,465,286 shares worth $334.69 million. Renaissance Technologies LLC cut its stake by 507,600 shares, holding 6,160,428 shares valued at $217.83 million.

Alkermes plc Stock Up 10.5%

Shares of Alkermes traded around $48.17 on Wednesday. The company boasts a market cap of $7.67 billion and a P/E ratio of 51.13. Its stock has a 52-week low of $25.17 and a high of $46.63, with a 50-day moving average of $37.84 and a 200-day moving average of $32.18. Alkermes has a beta of 0.334, indicating lower volatility compared to the broader market.

Recent Earnings

Alkermes reported revenue of $1.56 billion, with a revenue growth rate of 28.2%. The company posted an EPS of $0.90, a net margin of 9.77%, and a return on equity of 9.36%. The next earnings report is expected on July 28, 2026.

Insider Buying and Selling at Alkermes plc

Recent insider transactions at Alkermes included several planned sales. On June 12, 2026, Christopher Wright sold 2,000 shares at an average price of $45.10 under a planned sale. David Joseph Gaffin, EVP and CLO, sold 2,034 shares on June 4, 2026, at $43.05 per share, also as part of a planned transaction. Craig Hopkinson, EVP R&D and Chief Medical Officer, sold 9,000 shares at $41.67 and bought 5,000 shares at $19.34 on June 1, 2026.

Analysts Set New Price Targets

Analysts have maintained a positive outlook on Alkermes. On June 22, 2026, TD Cowen maintained a buy rating with a $50.00 price target. Needham reiterated its buy rating with a $54.00 target on June 18, 2026. RBC Capital also maintained a buy rating, setting a target of $56.00 on June 9, 2026. The consensus recommendation for Alkermes is a buy, with an average target price of $47.19 based on 16 analyst opinions.

About Alkermes plc

Alkermes plc is a biopharmaceutical company based in Dublin, Ireland. It focuses on developing and marketing drugs for conditions such as opioid and alcohol dependence, schizophrenia, and bipolar I disorder. The company offers several key products, including ARISTADA for schizophrenia and VIVITROL for alcohol and opioid dependence. Alkermes collaborates with companies like Janssen Pharmaceutica to advance its pipeline. Founded in 1987, Alkermes employs around 2,050 people.

Bottom Line

Loomis Sayles's decision to trim its Alkermes stake by 6.2% is a notable adjustment, reflecting the dynamic nature of institutional investments. Investors often track such filings to gauge institutional sentiment. It's important to remember that 13F filings reflect past positions and may not indicate current holdings.